# US 2013/0274182 A1 · Engineered polypeptides having enhanced duration of action

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0274182 A1
- Document ID: US20130274182A1
- Status: Published application
- Kind: A1
- Application number: 13/852,671
- Filed: 2013-03-28
- Published: 2013-10-17
- Earliest claimed: 2010-09-28
- Assignees: AstraZeneca Pharmaceuticals LP; Amylin Pharmaceuticals, Inc.
- Applicants: AstraZeneca Pharmaceuticals LP; Amylin Pharmaceuticals, LLC
- Inventors: Mary Erickson; David C. Litzinger; Soumitra S. Ghosh; Zijian Guo; Jonathan David Roth
- Web page: https://patentgrep.com/patent/US20130274182A1

## CPC

- C07K 14/5759: {Products of obesity genes, e.g. leptin, obese (OB), tub, fat}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K 14/575: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 38/2264: {Obesity-gene products, e.g. leptin}
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.

## Claims

### Claim 1

An engineered polypeptide comprising: an albumin binding domain polypeptide (ABD) and a first peptide hormone domain (HD1) selected from a leptin, a leptin analog or an active fragment thereof.

### Claim 2 (depends on 1)

The engineered polypeptide according to claim 1, further comprising a first linker (L1) covalently linked to said HD1.

### Claim 3 (depends on 1)

The engineered polypeptide according to claim 1, wherein said engineered polypeptide comprises said ABD as an N-terminal moiety and said HD1 as a C-terminal moiety.

### Claim 4 (depends on 1)

The engineered polypeptide according to claim 1, wherein said engineered polypeptide comprises said ABD as a C-terminal moiety and said HD1 as an N-terminal moiety.

### Claim 5 (depends on 1)

The engineered polypeptide according to claim 1, wherein said HD1 has at least 50% identity with an amino acid sequence selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12. SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33.

### Claim 6 (depends on 1)

The engineered polypeptide according to claim 1, wherein said ABD comprises an albumin binding motif (ABM) that consists of the amino acid sequence:
(SEQ ID NO: 34)
GVSD X5 YK X8 X9 I X11 X12 A X14 TVEGV X20 AL X23
X24 X25 I
wherein, independently of each other,
X5 is selected from Y and F;
X8 is selected from N, R and S;
X9 is selected from V, I, L, M, F and Y;
X1i is selected from N, S, E and D;
X12 is selected from R, K and N;
X14 is selected from K and R;
X20 is selected from D, N, Q, E, H, S, R and K;
X23 is selected from K, I and T;
X24 is selected from A, S, T, G, H, L and D; and
X25 is selected from H, E and D.

### Claim 7 (depends on 6)

The engineered polypeptide according to claim 6, wherein, independently of each other,
X5 is Y;
X8 is N;
X23 is T or I;
X24 is S or L; and
X25 is E or H.

### Claim 8 (depends on 7)

The engineered polypeptide according to claim 7, wherein the albumin binding motif comprises an amino acid sequence that is selected from the group consisting of:
(SEQ ID NO: 114)
GVSDYYKNLINKAKTVEGVEALTLHI
and
(SEQ ID NO: 115)
GVSDYYKNLINKAKTVEGVEALISEI.

### Claim 9 (depends on 1)

The engineered polypeptide according to claim 1, wherein said ABD comprises an albumin binding motif (ABM) that is not GVSDYYKNLINNAKTVEGVKALIDEI (SEQ ID NO:35).

### Claim 10 (depends on 2)

The engineered polypeptide according to claim 2, wherein the albumin binding domain polypeptide (ABD) comprises an amino acid sequence that is selected from the group consisting of:
(SEQ ID NO: 50)
LAEAKEDAIKELDKYGVSDYYKNLINKAKTVEGVEALTLHILAALP;
and
(SEQ ID NO: 51)
LAEAKEDAIKELDKYGVSDYYKNLINKAKTVEGVEALISEILAALP.

### Claim 11 (depends on 1)

The engineered polypeptide according to claim 1, wherein said ABD comprises the amino acid sequence:
(SEQ ID NO: 36)
LAEAK Xa Xb A Xc Xd EL Xe KY-[ABM]-LAALP
wherein
[ABM] is an albumin binding motif, and,
independently of each other,
Xa is selected from V and E;
Xb is selected from L, E and D;
Xe is selected from N, L and I;
Xd is selected from R and K;
Xe is selected from D and K;
the leucine at position 45 is present or absent;
the proline at position 46 is present or absent; and
wherein ABM consists of the amino acid sequence:
(SEQ ID NO: 34)
GVSD X5 YK X8 X9 I X11 X12 A X14 TVEGV X20 AL X23
X24 X25 I
wherein, independently of each other,
X5 is selected from Y and F;
X8 is selected from N, R and S;
X9 is selected from V, I, L, M, F and Y;
X11 is selected from N, S, E and D;
X12 is selected from R, K and N;
X14 is selected from K and R;
X20 is selected from D, N, Q, E, H, S, R and K;
X23 is selected from K, I and T;
X24 is selected from A, S, T, G, H, L and D; and
X25 is selected from H, E and D.

### Claim 12 (depends on 11)

The engineered polypeptide according to claim 11, wherein said ABD comprises an amino acid sequence having at least 85% identity with an amino acid sequence that is selected from the group consisting of SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, and SEQ ID NO:52.

### Claim 13 (depends on 12)

The engineered polypeptide according to claim 12, wherein said ABD comprises any one of the peptides selected from the group consisting of:
(SEQ ID NO: 38)
LAEAKVLANRELDKYGVSDFYKSYINRAKTVEGVHTLIGHILAALP,
(SEQ ID NO: 39)
LAEAKVLANRELDKYGVSDFYKRLINKAKTVEGVNALTHHILAALP,
(SEQ ID NO: 40)
LAEAKVLANRELDKYGVSDYYKNLINRARTVEGVHALIDHILAALP,
(SEQ ID NO: 41)
LAEAKVLANRELDKYGVSDYYKNIINRAKTVEGVRALKLHILAALP,
(SEQ ID NO: 42)
LAEAKVLANRELDKYGVSDFYKNLINRAKTVEGVSSLKGHILAALP,
(SEQ ID NO: 43)
LAEAKVLANRELDKYGVSDYYKNLINKAKTVEGVEALTLHILAALP,
(SEQ ID NO: 44)
LAEAKVLANRELDKYGVSDFYKNLINRAKTVEGVDALIAHILAALP,
(SEQ ID NO: 45)
LAEAKVLANRELDKYGVSDFYKSLINRAKTVEGVDALTSHILAALP,
(SEQ ID NO: 46)
LAEAKVLANRELDKYGVSDFYKNLINRAKTVEGVNSLTSHILAALP,
(SEQ ID NO: 47)
LAEAKVLANRELDKYGVSDFYKNVINKAKTVEGVEALIADILAALP,
(SEQ ID NO: 48)
LAEAKVLANRELDKYGVSDYYKNLINKAKTVEGVQALIAHILAALP,
(SEQ ID NO: 49)
LAEAKVLANRELDKYGVSDFYKRLINKAKTVEGVEALKLHILAALP,
(SEQ ID NO: 50)
LAEAKEDAIKELDKYGVSDYYKNLINKAKTVEGVEALTLHILAALP,
(SEQ ID NO: 51)
LAEAKEDAIKELDKYGVSDYYKNLINKAKTVEGVEALiseILAALP,
and
(SEQ ID NO: 52)
LAEAKEDAIKELDKYGVSDYYKRLISKAKTVEGVKALISEILAALP.

### Claim 14 (depends on 2)

The engineered polypeptide according to claim 2, wherein said linker L1 is a peptide of from 1 to 30 amino acids.

### Claim 15 (depends on 14)

The engineered polypeptide according to claim 14, wherein said linker L1 comprises a N-terminal TG dipeptide.

### Claim 16 (depends on 14)

The engineered polypeptide according to claim 14, wherein said linker L1 comprises a C-terminal AS dipeptide.

### Claim 17 (depends on 14)

The engineered polypeptide according to claim 14, wherein said linker L1 comprises an N-terminal TG dipeptide and a C-terminal AS dipeptide.

### Claim 18 (depends on 14)

The engineered polypeptide according to claim 14, wherein said linker L1 comprises an amino acids sequence that is selected from the group consisting of TG-(GGGS)1 (SEQ ID NO: 215), TG-(GGGS)2 (SEQ ID NO: 216), TG-(GGGS)3 (SEQ ID NO: 217), TG-(GGGS)4 (SEQ ID NO: 218), TG-(GGGS)5 (SEQ ID NO: 219), (GGGS)1-AS (SEQ ID NO: 220), (GGGS)2-AS (SEQ ID NO: 221), (GGGS)3-AS (SEQ ID NO: 222), (GGGS)4-AS (SEQ ID NO: 223), (GGGS)5-AS (SEQ ID NO: 224), TG-(GGGS)1-AS (SEQ ID NO: 225), TG-(GGGS)2-AS (SEQ ID NO: 226), TG-(GGGS)3-AS (SEQ ID NO: 227), TG-(GGGS)4-AS (SEQ ID NO: 228), and TG-(GGGS)5-AS (SEQ ID NO: 229).

### Claim 19 (depends on 1)

The engineered polypeptide according to claim 1, wherein said polypeptide further comprises one or more additional linkers.

### Claim 20 (depends on 1)

The engineered polypeptide according to claim 1, wherein said engineered polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85 SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, and SEQ ID NO:107.

### Claim 21 (depends on 1)

A method for treating a disease or disorder in a subject, comprising administering a engineered polypeptide according to claim 1 to a subject in need thereof in an amount effective to treat said disease or disorder.

### Claim 22 (depends on 21)

The method according to claim 21, wherein said disease or disorder is disease or disorder can be lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease, diabetes, type I diabetes, type II diabetes, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.

### Claim 23 (depends on 22)

The method according to claim 22, wherein said disease or disorder is lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes.

### Claim 24 (depends on 1)

A pharmaceutical composition comprising an engineered polypeptide according to claim 1 and a pharmaceutically acceptable excipient.

### Claim 25 (depends on 24)

The pharmaceutical composition according to claim 24, wherein said pharmaceutical composition is formulated as an injectable pharmaceutical composition.

### Claim 26 (depends on 24)

The pharmaceutical composition according to claim 24, wherein said pharmaceutical composition is formulated as a sustained release or long lasting pharmaceutical composition.

### Claim 27 (depends on 24)

The pharmaceutical composition according to claim 24 formulated for use in the treatment of lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease, diabetes (including type I and type II), nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD) and metabolic syndrome X.

### Claim 28 (depends on 1)

The engineered polypeptide according to claim 1, wherein said HD1 is selected from the group consisting of:
(a) the amino acid sequence 1-146 of a leptin selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, and SEQ ID NO:146; in which a different amino acid is substituted in one or more of the following positions and retaining the same numbering (even in the absence of a glutaminyl residue at position 28): 4, 32, 33, 35, 50, 64, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111, 118, 136, 138, 142, and 145;
(b) the amino acid sequence of subpart (a) in which the glutaminyl residue at position 28 is absent;
(c) the amino acid sequence of subparts (a) or (b) in which a methionyl residue is added at the N-terminus;
(d) a leptin consisting of a fragment of the amino acid sequence of (a), (b), or (c) selected from the group consisting of:
(i) amino acids 98-146;
(ii) amino acids 1-32;
(iii) amino acids 40-116;
(iv) amino acids 1-99 and 112-146;
(v) amino acids 1-99 and 112-146 in which one or more of amino acids 100-111 is placed between amino acids 99 and 112;
(vi) the amino acid sequence of subpart (i) wherein one or more of amino acids 100, 102, 105, 106, 107, 108, 111, 118, 136, 138, 142, and 145 is substituted with another amino acid;
(vii) the amino acid sequence of subpart (ii) wherein one or more of amino acids 4, 8 and 32 is substituted with another amino acid;
(viii) the amino acid sequence of subpart (iii) wherein one or more of amino acids 50, 53, 60, 64, 66, 67, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111 and 112 is replaced with another amino acid;
(ix) the amino acid sequence of subpart (iv) wherein one or more of amino acids 4, 8, 32, 33, 35, 48, 50, 53, 60, 64, 66, 67, 68, 71, 74, 77, 78, 89, 97, 112, 118, 136, 138, 142, and 145 is replaced with another amino acid; and
(x) the amino acid sequence of subpart (v) wherein one or more of amino acids 4, 32, 33, 35, 50, 64, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111, 118, 136, 138, 142, and 145 is replaced with another amino acid;
(xi) the amino acid sequence of any of subparts (i)-(x) wherein a methionine has been added at the N-terminus;
(e) the amino acid sequence of any of subparts (a) through (d) wherein said amino acid sequence is attached to a chemical moiety;
(f) the amino acid sequence of subpart (e) wherein said chemical moiety is a water soluble polymer moiety;
(g) the amino acid sequence of subpart (f) wherein said water soluble polymer moiety is selected from the group consisting of: polyethylene glycol, an ethylene glycol/propylene glycol copolymer, a carboxymethylcellulose, a dextran, a polyvinyl alcohol, a polyvinyl pyrolidone, a poly-1,3-dioxolane, a poly-1,3,6-trioxane, an ethylene/maleic anhydride copolymer, a polyaminoacid homopolymer, a polyaminoacid random copolymer, an albumin, an Fc protein, a poly(n-vinyl pyrolidone)polyethylene glycol, a propylene glycol homopolymer, a polypropylene oxide/ethylene oxide copolymer, a polyoxyethylated polyol, a polyvinyl alcohol, a polyethylene glycol propionadehyde, a succinate, and a styrene;
(h) the amino acid sequence of subpart (g) wherein said water soluble polymer moiety is a polyethylene glycol; and
(i) the amino acid sequence of subpart (g) wherein said water soluble polymer is a polyamino acid-selected from the group consisting of: an albumin, an antibody, an Fc protein, and a polylysine moiety.

### Claim 29 (depends on 28)

The engineered polypeptide according to claim 28, wherein said HD1 comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, and SEQ ID NO:146; wherein one or more amino acid substitutions have been made.

### Claim 30 (depends on 1)

The engineered polypeptide according to claim 1, wherein said HD1 is SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145 or SEQ ID NO:146.

### Claim 31

A method of treating obesity in a subject comprising peripherally administering therapeutically effective amounts of at least two different anti-obesity agents, wherein at least one anti-obesity agent is an amylin, an amylin analog, an amylin agonist, or an amylin derivative (i.e. an amylin agent) and at least one anti-obesity agent is an engineered polypeptide comprising: an albumin binding domain polypeptide (ABD); and a first peptide hormone domain (HD1) selected from a leptin, a leptin analog or an active fragment thereof.

### Claim 32

A method of reducing body weight in a subject comprising peripherally administering therapeutically effective amounts of at least two different anti-obesity agents, wherein at least one anti-obesity agent is an amylin, an amylin analog, an amylin agonist, or an amylin derivative (i.e. an amylin agent) and at least one anti-obesity agent is an engineered polypeptide comprising: an albumin binding domain polypeptide (ABD); and a first peptide hormone domain (HD1) selected from a leptin, a leptin analog or an active fragment thereof.
